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NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful
polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the
maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man.
NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10mg DXR
equivalentmin
 1. The starting dose was 6mg DXR equivalentm
 2, and the dose was escalated according to the accelerated titration
method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4
neutropenia was observed at doses of 50 and 67mgm
 2. Common nonhaematological toxicities were mild alopecia, stomatitis, and
anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67mgm
 2 (grade 4 neutropenia lasting more
than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The
C5min and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23
patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced
only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be
50mgm
 2 every 3 weeks.
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Agents categorised as drug delivery systems (DDSs) have been
developed based on the characteristic macroscopic features of
solid tumours, such as hypervascularity, an irregular vascular
architecture, the presence of several vascular permeability factors
stimulating extravasation within the cancer, and the relatively poor
drainage of macromolecules and particulates from cancer tissue.
These characteristics, which are unique to solid tumours,
constitute the basis of the enhanced permeability and retention
(EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).
Macromolecules have long plasma half-lives because they are too
large to pass through normal vessel walls unless they are trapped
by the reticuloendothelial system (RES) in the cells of various
organs. Such macromolecular agents can diffuse out of tumour
blood vessels, reach the solid tumour tissue, and be retained for a
long period because of the EPR effect.
To maximise the EPR effect, several techniques have been
developed to modify the structures of drugs and to construct drug
carriers. Doxil is comprised of doxorubicin (DXR) encapsulated in
STEALTHt liposomes, which are composed of a phospholipid
bilayer with surface-bound methoxypolyethyleneglycol. Doxil
recently received the US Food and Drug Administration’s (FDA)
approval for use in the treatment of Kaposi sarcoma or ovarian
cancer after the clinical benefits of this drug were clearly shown in
recent clinical trials (Muggia et al, 1996; Stewart et al, 1998;
Gordon et al, 2001).
Polymeric micelles have also been utilised as a drug carrier
system. The original form of micellar DXR contained two trapped
components: a DXR monomer and a DXR dimer in the inner core
(Yokoyama et al, 1990a,b). However, the lyophilised micelle
containing DXR dimers became insoluble after long periods of
storage. To improve the solubility of this drug carrier system, a
new type of polymeric micelle containing only the DXR monomer,
known as NK911, has been developed (Nakanishi et al, 2001). The
DXR monomers, rather than the DXR dimers, were thought to play
a major role in the antitumour activity of the original micellar DXR
drug preparation. The DXR dimers, on the other hand, were
thought to stabilise the drug’s conformation. Thus, NK911, which
only contains DXR monomers, is less stable in aqueous media than
the original form of micellar DXR (Nakanishi et al, 2001; Tsukioka
et al, 2002).
Both polyethyleneglycol (PEG)-liposomal and micellar DXR
have longer plasma half-lives, accumulate in tumours more
effectively because of the EPR effect, and exhibit a stronger
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lantitumour activity than free DXR when administered in mice.
Both the plasma area under the concentration–time curve (AUC)
and the tumour AUC of NK911 are, however, lower than those of
doxil because NK911 is less stable in the bloodstream than doxil
(Working et al, 1994; Nakanishi et al, 2001). At this stage, however,
we have no definitive idea as to which formulation exerts a
superior antitumour activity in vivo because an evaluation of the
activity in vivo cannot be based solely on the enhanced tumour
AUC; several additional factors, including the efficiency of the free
drug inside the formulation and the distribution of the free drug
throughout the tumour tissue, must also be taken into considera-
tion. Proper selection of the type of DDS formulation is likely to
depend on the tumour vessel density of the tumour tissue.
With this in mind, we conducted a phase I clinical trial on the
use of NK911 in patients with solid tumours. The study was
performed at the National Cancer Center Hospital, Tokyo, Japan.
Our objectives were to assess the safety and toxicity profile of
NK911 and to determine the maximum-tolerated dose (MTD), the
phase II recommended dose, and the pharmacokinetics of NK911
in man.
PATIENTS AND METHODS
The study protocol was reviewed and approved by the Institutional
Review Board of the National Cancer Center, Tokyo.
Therapeutic agent
Figure 1 shows the schematic structure of NK911, a DXR-
entrapped polymeric micelle formulation. The polymeric micelle
consists of a PEG–poly(aspartic acid) block copolymer conjugated
with DXR. Polyethyleneglycol is believed to form the outer shell of
the micelle, producing a ‘stealth’ effect that prevents NK911 from
being captured by the RES. The DXR-conjugated poly(aspartic
acid) chain is hydrophobic and is believed to form the
hydrophobic inner core of the micelles in aqueous media. The
hydrophobic inner core enables NK911 to entrap a sufficient
amount of DXR. NK911 has a diameter of about 40nm (Nakanishi
et al, 2001).
Patients
Patients with metastatic or recurrent solid tumours refractory to
conventional chemotherapy and for whom no effective therapy was
available were eligible for enrolment in this study, provided that
the following criteria were met: a histologically confirmed
malignant tumour; a performance status of p2; an age of X20
and o75 years; a normal haematological profile (neutrophil
count X2000ml
 1, platelet count X100000ml
 1, haemoglobin
X8gdl
 1); normal hepatic function (total bilirubin level
p1.5mgdl
 1, aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) p2.5 times the upper normal limit);
normal renal function (serum creatinine p1.5mgdl
 1); normal
cardiac function (New York Heart Association (NYHA) classifica-
tion of p1); normal pulmonary function (PaO2 X60mgHg); no
chemotherapy within 4 weeks (6 weeks for nitrosourea or
mitomycin C chemotherapy) of the administration of NK911;
and a life expectancy of more than 2 months. Patients with any
serious infection (including hepatitis B, hepatitis C, or HIV),
symptomatic brain metastasis, and pre-existing cardiac disease
(including congestive heart failure, myocardial infarction, or
angina pectoris within 3 months) were ineligible for enrolment
in the study. Patients were also excluded if they were pregnant or
lactating or showed signs of gastrointestinal bleeding. Addition-
ally, any patients whom the investigators considered ineligible
were excluded. Written informed consent was obtained from all
patients.
Drug administration
NK911 was dissolved in sterile phosphate-buffered saline
for injection at room temperature at a concentration of
2mg DXR equivalentml
 1. NK911 solution was infused intrave-
nously using an electric pump at a speed of 10mg DXR
equivalentmin
 1.
Dosage and dose escalation
The starting dosage of NK911 was 6mg DXR equivalent, which is
one-tenth of the LD10 in rats. NK911 was administered once every
3 weeks, and the treatment was continued unless a severe adverse
event or disease progression was observed. Dose escalation was
performed according to the previously described accelerated
titration method (Simon et al, 1997). Toxicity was graded from 1
to 4 using the NCI common toxicity criteria (version 12).
Intrapatient dose escalation was not permitted. The dose-limiting
toxicity (DLT) was confirmed in at least six out of 23 patients. The
MTD was defined as the level at which three out of six patients
experienced a DLT. The recommended dosage for a phase II trial
was defined by the Efficacy and Safety Assessment Committee,
based on the safety and efficacy results of this trial. The DLT was
defined as grade 4 neutropenia lasting more than 5 days or an
associated neutropenic fever of more than 38.51C, a platelet count
of less than 25000ml
 1, or grade 3 or higher nonhaematological
toxicity, with the exception of nausea, vomiting, appetite loss,
constipation, and hyperglycaemia.
Pretreatment assessment and follow-up care
A complete medical history and physical examination, perfor-
mance status evolution, complete blood cell count (CBC), blood
chemistry, urinalysis, electrocardiogram (ECG), and a computed
tomography (CT) examination or an upper gastrointestinal (GI)
series were performed in each patient. Other examinations were
PEG
Free DXR
Formulation in aqueous media 
Conjugated DXR
Poly(aspartic acid) 
NK911
Incorporated DXR
Conjugated DXR
DXR-conjugated polymer  Active component 
Figure 1 Schematic structure of NK911. A polymeric micelle carrier of
NK911 consists of a block copolymer of PEG (molecular weight of about
5000) and poly(aspartic acid) (about 30 units). Polyethyleneglycol is
believed to be the outer shell of the micelle. NK911 has a highly
hydrophobic inner core, and therefore can entrap sufficient amounts of
DXR.
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lperformed only in the presence of a specific clinical indication.
Patients were physically examined everyday until the second
administration of NK911; CBC and blood chemistry tests were
performed on days 1, 2, and 4 and weekly thereafter. Electro-
cardiogram and ultrasonic cardiography studies were repeated
prior to each administration of NK911. Tumour markers were
also measured prior to each administration. Tumour response
was evaluated according to the WHO guidelines (World Health
Organization, 1979). A complete response (CR) was defined as the
disappearance of the cancerous lesion(s), and a partial response
(PR) was defined as a reduction of more than 50% of the sum of
the bidimensional products when the results for two observations,
separated by at least 4 weeks, were compared. Stable disease (SD)
was defined as a reduction of less than 50% or a growth of less than
25% over a period of at least 4 weeks. Progressive disease (PD) was
defined as a growth of more than 25%, the appearance of new
malignant lesion(s), or the unequivocal worsening of other clinical
evidence of malignancy.
High-performance liquid chromatography determination
of DXR and its metabolites
Doxorubicin and its metabolites (doxorubicinol and aglycones)
were extracted from human plasma and urine using Abselut
NEXUS cartridges (Varian), pretreated with methanol (2ml), 1%
phosphoric acid (1ml), and sodium phosphate buffer (2ml of
25mmoll
 1 NaH2PO4 (pH 4) containing 0.2% sodium lauryl
sulphate). Daunorubicin was added to the plasma (0.5ml) or urine
(0.1ml) samples as an internal standard. The diluted plasma or
urine was applied to the above-mentioned cartridges and then
washed with distilled water (1ml) or 40% methanol (2ml) and
eluted with methanol (2ml). The eluate was evaporated to dryness
at 401C under a stream of nitrogen. The residue was dissolved in
sodium phosphate buffer (200ml of 25mmoll
 1 NaH2PO4 (pH 4)
containing 0.2% sodium lauryl sulphate/acetonitrile¼75/25,
vv
 1), and 50ml of the resulting solution was injected onto the
analytical column. The analyses of DXR and its metabolites in
plasma and urine samples were performed using high-perfor-
mance liquid chromatography (HPLC) with fluorescence detection.
The DXR concentrations determined in the present Phase I study
represented the total drug concentrations (both micelle-entrapped
and nonencapsulated). The HPLC system (HP1100 series, Hewlett
Packard) consisted of a binary pump, an automatic sample
injector, a reversed-phase CAPCELL PAK C8 (2.0mm i.d. 
150mm, 5mm, SHISEIDO), and a fluorescence detector with
excitation and emission wavelengths of 500 and 550nm, respec-
tively. A gradient elution was employed, consisting of 25mmoll
 1
NaH2PO4 (pH 4) containing 0.2% sodium lauryl sulphate/
acetonitrile at ratios of 75/25 to 55/45 (vv
 1), at a flow rate of
0.2mlmin
 1.
Pharmacokinetic analysis
The pharmacokinetic parameters were calculated after fitting the
data to a three-compartment model using the Win Nonlin
program. The plasma DXR concentration, C(t), at each time (t),
was computed using the equation
CðtÞ¼D=T ½A=aðeaT   1Þe aðt þ TÞþB=bðebT   1Þe bðtþTÞ
þ C=gðegT   1Þe gðtþTÞ 
where D is the dose and T is the infusion time.
The AUC, total clearance (CLtot), volume of distribution at
steady state (Vss), area under the first moment curve (AUMC),
volume of distribution of the central compartment (V1), half-lives
(t1/2a, t1/2b, t1/2g), and mean residence time (MRT) of DXR were
calculated using the equations listed below.
AUC ¼A=a þ B=b þ C=gðnghml
 1Þ
CLtot ¼dose=AUCðmlmin 1 kg
 1Þ
Vss ¼dose AUMC=ðAUCÞ
2 ðlkg  1Þ
V1 ¼dose=A þ B þ Cðlkg  1Þ
T1=2 ¼0:693=kðhÞðk ¼ a; b; gÞ
MRT ¼AUMC=AUCðhÞ
RESULTS
Patient characteristics
A total of 23 eligible patients were recruited for the study. Their
clinical characteristics are shown in Table 1. With the exception of
one patient with a leiomyosarcoma, all the patients had received
chemotherapy prior to enrolment in the study. Prior therapies
ranged from 0 to 6 regimens of chemotherapy. None of the patients
had received anthacycline chemotherapy. As a deviation from the
ordinary phase I trial protocol, patients with metastatic pancreatic
cancer were deliberately recruited, based on the previously
described characteristics of NK911. All patients were included in
the safety and response analyses.
Dosing
Dosage escalation started at 6.0mg DXR equivalentm
 2 and was
increased up to 67mg DXR equivalentm
 2. Infusion time ranged
from 58s to 12min and 15s depending on the absolute dosage of
NK911. In total, 63 administrations were performed in 23 patients.
A total of 14 patients received more than two administrations. The
maximum number of treatments was 10 courses at level 3; the
average number of administrations at all levels was 2.7 courses. Up
until the third level, grade 2 toxicity was not observed during the
first course of chemotherapy. According to the original protocol,
the dosage of NK911 should have been doubled for each escalation.
However, the safety committee recommended that the dosage
should be raised by 50%, instead of 100%, at level 4 and that a
modified Fibonacci escalation method should be implemented.
Therefore, we recruited three patients at this dosage level and
restarted the dose identification study using a modified Fibonacci
method.
Haematological toxicity
As shown in Table 2, significant myelosuppression was not
observed up to level 4. At level 5, two patients died because of
tumour progression. The progression of the disease was confirmed
Table 1 Patient characteristics
Number of patients 23
Male/female 15/8
Age (years)
Median 61.5
Range 48–72
ECOG PS
Median 1
06
11 7
Prior treatment chemotherapy regimens
Median 2
Range 0–6
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lby autopsy in both cases. Since these two patients could not be
assessed for safety, an additional two patients were enrolled at level
5. Two patients developed grade 3 neutropenia and one patient
developed grade 4 neutropenia. However, none of the patients
developed a DLT at this dosage level. At level 6, all six patients who
entered at this level developed grade 4 neutropenia; three of the six
patients appeared to have acquired a DLT (grade 4 neutropenia
lasting for more than 5 days). Based on these results, level 6 was
considered to be the MTD, with neutropenia as the DLT. Since a
dosage of 50mgm
 2 was considered to be the recommended
dosage for phase II studies, an additional six patients were enrolled
at a dosage of 50mgm
 2; one of these six patients developed a
DLT in the form of febrile grade 4 neutropenia.
Nonhaematological toxicity
The NK911 injection was generally uneventful and well tolerated.
The major nonhaematological toxicities were nausea, vomiting,
and anorexia. All of these toxicities were controllable. Severe
mucositis and skin toxicity in the form of hand-foot syndrome did
not occur. Alopecia was also mild, and only three patients
experienced grade 2 alopecia after repeated doses of NK911 at
levels 5 and 6 (Table 3). A few patients at level 5 or 6 developed a
grade 2 elevation in AST or ALT, but these changes were transient.
No pain or local toxicity in the area of injection was observed in
any of the patients treated with NK911, except in one patient
treated at level 2. No infusion-related reactions were observed in
any cases; such reactions sometimes occur during liposomal drug
administration. Cardiac function was monitored at baseline and
serially in all patients enrolled in the study. Clinical congestive
heart failure did not occur. The left ventricular ejection fraction
did not decrease significantly from the baseline level in any of the
patients except for one patient treated at level 5 whose LVEF
decreased to 45% after one cycle. Since this patient was transferred
to another hospital, this change could not be confirmed.
Pharmacokinetics
The plasma concentrations of DXR after the intravenous infusion
of NK911 were determined in all of the patients enrolled in the
present phase I study; the results are shown in Figure 2. The C5min
and AUC parameters increased at doses between 6 and 67mgm
 2,
as shown in Figure 3. The peak plasma concentrations ranged from
586.8ngml
 1 at a dose level of 6mgm
 2 to 6188.2ngml
 1 at a
dose level of 67mgm
 2.
The pharmacokinetic parameters are summarised in Table 4.
The initial distribution half-life (t1/2a) was about 5–8min, t1/2b was
1.6–4.7h, and t1/2g was 29.4–241.4h. The V1 was 0.116 –
0.183lkg
 1. The CLtot was 3.9–9.8mlmin
 1kg
 1, and the Vss
was 11.7–52.3lkg
 1. No significant differences in these para-
meters were seen among patients, with the exception of patients
receiving doses of 6, 12, and 24mgm
 2. These observations may
be attributed to the fact that DXR was difficult to detect at 168h
after dosing at levels of below 24mgm
 2, possibly resulting in an
underestimation or an overestimation of the tails of the clearance
curve. The half-lives (t1/2a, t1/2b, and t1/2g) were longer for NK911
than for free DXR (Mross et al, 1988). The AUC of NK911 was two-
fold larger than that of free DXR at a dose of 50mgm
 2. The Vss
and CLtot of NK911 were lower than those of free DXR. As
expected, the parameters for NK911 were more than 100-fold lower
than those previously described for doxil (Gabizon et al, 1994).
The cumulative urinary excretion rates of DXR and its
metabolites (0–72h) after the administration of NK911 were
7.1–16.6%, similar to those after the administration of free DXR.
Table 2 Haematological toxicity: cycle 1
Leucocytopenia Neutropenia Thrombocytopenia
Grade Grade Grade
Dose level (mgm
 2) n 12341 2 3 41 2 3 4
6 1 0 0 0 00000 0 0 0 0
1 2 1 0 0 0 00000 0 0 0 0
2 4 1 1 0 0 01000 0 0 0 0
3 6 3 1 0 0 00100 0 0 0 0
5 0 1 1 3 5 3 01352 2 0 0 0
6 7 6 0 1 5 00006 3 0 1 0
Total 23 5 6 8 0 2458 5 0 1 0
Table 3 Nonhaematological toxicity
Grade
1 2 3 4 Total
Nausea 10 2 3 0 15
Vomiting 5 2 1 0 8
Anorexia 11 3 3 0 17
Fatigue 1 1 0 0 2
Stomatitis 5 0 0 0 5
Alopecia 12 0 — — 12
There was no DLT regarding nonhaematological toxicities within this trial.
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Figure 2 Mean plasma levels of doxorubicin following the intravenous
administration of NK911 at dosages of 6, 12, 24, 36, 50, and 67mgm
 2 in
23 patients.
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lTherapeutic response
At the time of the study’s completion, eight patients (including one
patient with colonic cancer and two patients with stomach cancer)
had exhibited a stable disease for longer than 4 weeks (Table 5). A
partial response was seen in one patient with metastatic pancreatic
cancer who had been treated at a dosage level of 6; the size of the
liver metastasis had decreased by more than 50%, compared to the
baseline scan, in this patient (Figure 4A and B). The tumour
marker (CA19-9 and CEA) levels in this patient had also decreased
remarkably (Figure 4C). This patient had previously undergone
gemicitabine chemotherapy. Initially, this patient received an
NK911 dosage of 67mgm
 2. The dosage was decreased to
50mgm
 2 for the second course, however, because the patient
experienced grade 4 neutropenia. The antitumour response was
maintained even after the dosage was reduced.
DISCUSSION
The utility of polymeric micelles in cancer chemotherapy was
demonstrated in mice for the first time using DXR-incorporated
polymeric micelles in the early 1990s (Yokoyama et al, 1990a,b,
1991). The original form of micellar DXR contained two entrapped
components, DXR monomers and DXR dimers, in the inner core.
The DXR dimers were thought to contribute to the stabilisation of
the micellar DXR conformation. However, the DXR dimers in this
formulation caused freeze-dried samples of micellar DXR to
become water-insoluble after prolonged storage. To improve the
solubility of micellar DXR, a new polymeric micellar preparation,
NK911, containing only DXR monomers was created (Nakanishi
et al, 2001).
In this phase I study, the toxicity spectrum of NK911 resembled
that of free DXR: the DLT was neutropenia, and no adverse effects
appeared other than those also encountered with the use of free
DXR. Regarding nonhaematological toxicities, nausea and vomit-
ing were mild. Mucositis was also rare and mild. No infusion-
related reactions, which are sometimes seen in cases of liposomal
drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart
et al, 1998; Gordon et al, 2001), occurred in this trial. Ultimately,
this phase I study showed that the recommended dosage of NK911
(50mgm
 2) using a 3-week schedule was similar to the
recommended dosage of free DXR (40–60mgm
 2). In preclinical
studies using several kinds of animals, the pharmacokinetics of
NK911 differed from those of free DXR (Nakanishi et al, 2001).
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Figure 3 Correlations between dosage and AUC0–inf (A) and C5min(B)
after a single intravenous administration of NK911.
Table 4 Pharmacokinetic parameters
Dose (mgm
 2) nt 1/2a (min) t1/2b (h) T1/2c (h) AUC0–inf (nghml
 1)C L tot (mlmin
 1kg
 1) Vss (lkg
 1) V1 (lkg
 1)M R T 0–inf
NK911
6 1 5.1 2.3 159.7 601.4 3.9 36.8 0.116 158.2
12 1 5.0 1.6 29.4 495.3 9.8 11.7 0.153 19.9
24 1 6.8 4.7 241.4 2257.7 46.1 52.3 0.163 210.9
36 3 6.670.5 2.870.0 54.874.8 2460.57469.9 6.471.2 12.072.3 0.183.1370.030 32.078.8
50 11 7.570.7 2.870.3 64.278.9 3262.77425.2 6.771.1 14.973.6 0.16770.035 37.078.2
67 6 8.171.1 2.970.5 73.6721.4 4174.17471.2 6.871.1 16.376.1 0.18370.051 41.2717.8
DXR
a
50 7 2.470.9 0.871.1 25.8711.4 1620.371062.9 14.475.6 24712 — —
PLD
b
50 14 84 45.9 — 902000 0.02 0.08 — 62.7
aCited from Mross et al (1998).
bCited from Gabizon et al (1994).
Table 5 Antitumour activity
Primary tumour n PR SD PD
Pancreas 7 1 1 5
Colorectal 7 0 4 3
Oesophagus 3 0 1 2
Gall bladder 3 0 0 3
Stomach 2 0 2 0
Leiomyosarcoma 1 0 0 1
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lWhen compared with free DXR, NK911 exhibited longer half-
lives (t1/2a, t1/2b, and t1/2g), a lower CLtot, and a larger AUC; these
findings suggest that the circulation of NK911 in plasma was
prolonged. Furthermore, the extent of the NK911 distribution in
the tumour tissue was thought to differ from that of free DXR
because of the smaller Vss of NK911 compared with that of free
DXR. The V1 of NK911 was smaller than the volume of
extracellular fluid in humans, which may lead to a smaller
distribution of NK911 in tumour tissue during the early phase of
chemotherapy. Although the value of V1 in humans after the
injection of free DXR has not been reported, the V1 of free DXR
was two-fold larger than that of NK911 in a dog model and a
different distribution in the early phase was observed (data not
shown); a similar tendency in humans is expected. As mentioned
above, the micelle-forming ability of NK911 seems to result in
different physicochemical behaviours and a specific retention in
plasma, compared with DXR, because NK911 circumvents the early
distribution phase. The early pharmacokinetic phase may repre-
sent a very important stage in the overall behaviour of DXR in the
body (Robert et al, 1987). Therefore, the inherent characteristic
pharmacokinetics of NK911 in human subjects seems to be useful
and significant for the enhancement of clinical responses to DXR.
Concerning the release of DXR from the conjugated block
copolymer, the DXR concentrations in plasma were assessed after
administering a DXR-conjugated polymer in a dog model. The
released DXR concentration from the polymer was estimated to be
100-fold less than that of NK911 containing the same amount of
DXR-conjugated polymer in dogs. Consequently, conjugated DXR
is likely to have little effect on the plasma DXR concentration after
the injection of NK911 in patients. When [
14C]DXR-conjugated
polymer was intravenously administered to rats, the polymer was
excreted via both urine and faeces (urine:faeces¼2:1). In the rat
urine, several kinds of fragmented polymers derived from the
DXR-conjugated polymer were observed, as well as a nonfrag-
mented polymer. In rat faeces, only the fragmented polymers were
observed, and [
14C]DXR was not seen in either urine or faeces.
These results indicated that the DXR-conjugated polymer was
excreted after extensive metabolism, but that the free DXR was
hardly released from the polymer. Until now, the structure of the
excreted high-molecular fragments could not be determined
because of the difficulty in developing an analytical methodology
for these molecular species. In the present clinical trial, which
examined the urinary excretion of the physically trapped DXR in
NK911, the excretion rate was similar to that of free DXR over a
72-h period. The present results suggest that the major route
of excretion of DXR and its metabolites after NK911 injection
in human subjects is likely biliary, the same as for DXR
administration.
When compared with the historical data for doxil (Gabizon
et al, 1994), the plasma AUC of NK911 was more than 100-fold
lower than that of doxil, and the plasma clearance of NK911
was approximately 400-fold higher than that of doxil at a
DXR equivalent dosage of 50mgm
 2. These results indicate
that NK911 is less stable in plasma than doxil, since the
DXR dimers in the micellar DXR have not been included in
NK911 for the reason described earlier. Thus, doxil appears
to deliver DXR to solid tumours via the EPR effect more
efficiently than NK911, since doxil is more stable in the
bloodstream. However, the Vss of NK911 at a dose of
50mgm
 2 was about 180-fold higher than that of doxil at the
same dose level. This observation suggests that the distribution of
DXR in tumour tissue may be wider in the case of NK911
administration compared to that of doxil, once each formulation
extravasates from the tumour vessels. Therefore, to determine
whether doxil is more effective for the treatment of solid tumours
than NK911, several factors must be considered, including drug
pharmacokinetics, pharmacodynamics, tumour vasculature, the
tumour interstitium, the efficiency of drug release from the
formulation, and the distribution of free drug throughout
the tumour tissue.
In conclusion, the toxicity characteristics and antitumour
activity of NK911 justify its continued clinical evaluation. A phase
II clinical trial of NK911 for the treatment of metastatic pancreatic
cancer is ongoing.
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